First Manhattan
IOVA icon

First Manhattan’s Iovance Biotherapeutics IOVA Stock Holding History

First Manhattan’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$116K Sell
27,998
-1,000
-3% -$3.8K ﹤0.01% 733
2026
Q1 		$102K Hold
28,998
– – ﹤0.01% 741
2025
Q4 		$79.2K Sell
28,998
-25,302
-47% -$58.5K ﹤0.01% 720
2025
Q3 		$118K Buy
+54,300
New +$128K ﹤0.01% 700
2024
Q2 		– Sell
-550
Closed -$8.15K – 978
2024
Q1 		$8.15K Buy
+550
New +$6.4K ﹤0.01% 1134

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

First Manhattan's IOVA Position: Q2 2026 in Review

First Manhattan reduced its Iovance Biotherapeutics (IOVA) stake by 3.4% in Q2 2026, selling an estimated $3.8K and leaving 27,998 shares worth $116K. The position accounts for ﹤0.01% of the portfolio, ranked #733.

First Manhattan first reported a position in IOVA in Q1 2024 and has held it in 5 quarters since. The position peaked at $118K in Q3 2025. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • First Manhattan held 27,998 shares of Iovance Biotherapeutics worth $116K as of Q2 2026.
  • First Manhattan sold 1,000 Iovance Biotherapeutics shares in Q2 2026, an estimated $3.8K.
  • Iovance Biotherapeutics made up ﹤0.01% of First Manhattan's portfolio in Q2 2026, its #733 holding.
  • First Manhattan first reported a position in Iovance Biotherapeutics in Q1 2024 and has held it in 5 quarters since.
  • First Manhattan's Iovance Biotherapeutics position peaked at $118K in Q3 2025.
  • 293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on First Manhattan's 13F filing for Q2 2026, filed 14 Aug 2026.